How have EPGNY shares performed in 2024?

Epigenomics' stock was trading at $2.39 at the beginning of the year. Since then, EPGNY stock has increased by 0.0% and is now trading at $2.39. View the best growth stocks for 2024 here .

How do I buy shares of Epigenomics?

Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:EPGNY

Epigenomics (EPGNY) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EPGNY Stock Alerts

$2.39

0.00 (0.00%)

(As of 04/6/2023)

Compare

Today's Range: $2.39
▼
$2.39
50-Day Range: $2.39
▼
$2.39
52-Week Range: $2.01
▼
$2.39

Volume: N/A
Average Volume: 100 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Epigenomics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Epigenomics Stock (OTCMKTS:EPGNY)

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

EPGNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EPGNY Stock News Headlines

March 14, 2024 | markets.businessinsider.com

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

January 31, 2024 | markets.businessinsider.com

EQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

October 10, 2023 | markets.businessinsider.com

EQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023

October 10, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023

September 20, 2023 | finance.yahoo.com

Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics

September 14, 2023 | benzinga.com

New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting

August 10, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG publishes financial results for the first six months 2023

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

July 24, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets

July 24, 2023 | finance.yahoo.com

New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG

July 3, 2023 | finance.yahoo.com

Estimating The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

June 12, 2023 | marketwatch.com

Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5 Mln

May 19, 2023 | uk.news.yahoo.com

Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns

May 19, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resigns

April 13, 2023 | uk.finance.yahoo.com

Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns

April 12, 2023 | markets.businessinsider.com

EQS-Adhoc: Epigenomics AG: Changes in the Management

April 12, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns

March 20, 2023 | uk.finance.yahoo.com

Epigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Act

March 14, 2023 | benzinga.com

Sample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts Sector

March 10, 2023 | uk.finance.yahoo.com

Epigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)

February 21, 2023 | marketwatch.com

Personalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research Report

January 27, 2023 | uk.finance.yahoo.com

Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski

January 27, 2023 | markets.businessinsider.com

EQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski

December 23, 2022 | markets.businessinsider.com

EQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG share

December 21, 2022 | markets.businessinsider.com

EQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022

December 14, 2022 | markets.businessinsider.com

EQS-Adhoc: Epigenomics Releases Performance Data on Next Generation Test

See More Headlines

Receive EPGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: OTCMKTS:EPGNY
CUSIP: N/A
CIK: N/A
Web: www.epigenomics.com
Phone: (493) 024-3450
Fax: N/A
Employees: 32
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Gregory K. Hamilton (Age 52)
CEO & Member of the Exec. Board
Comp: $828.44k
Dr. Andrew A. Lukowiak Ph.D. (Age 50)
Pres & Chief Scientific Officer
Comp: $387.44k
Mr. Jens Ravens (Age 52)
CFO & Member of Exec. Board
Frederic Hilke
Investor Relations Officer
Dr. Noel Thomas Doheny
Chief Exec. Officer of Epigenomics Inc.

Key Competitors

View All Competitors

EPGNY Stock Analysis - Frequently Asked Questions

How have EPGNY shares performed in 2024?: Epigenomics' stock was trading at $2.39 at the beginning of the year. Since then, EPGNY stock has increased by 0.0% and is now trading at $2.39.
View the best growth stocks for 2024 here.
How do I buy shares of Epigenomics?: Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EPGNY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Epigenomics (EPGNY) Stock Price, News & Analysis

About Epigenomics Stock (OTCMKTS:EPGNY)

EPGNY Stock Price History

EPGNY Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EPGNY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info